Posted by Michael Wonder on 16 Feb 2022
Moderna's COVID-19 vaccine (Spikevax) provisionally approved for use in individuals 6 years and older
17 February 2022 - The TGA has provisionally approved the Moderna COVID-19 vaccine, Spikevax, for use in individuals aged 6 years and older.
The decision follows the provisional approvals granted by the TGA to Moderna for the use of Spikevax in individuals aged 12 years and older on 3 September 2021, and on 7 December 2021 the Spikevax booster dose for use in adults 18 years and older.
